Cargando…
Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma
BACKGROUND: Despite the rise in the use of immune checkpoint blockade drugs (ICBs) in recent years, there are no ICB drugs that are currently approved or under large-scale clinical trials for glioblastoma (GBM). T-cells, which mainly mediate adaptive immunity, are an important part of the tumor immu...
Autores principales: | Yan, Zihao, Chu, Siwen, Zhu, Chen, Han, Yunhe, Liang, Qingyu, Shen, Shuai, Cheng, Wen, Wu, Anhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710057/ https://www.ncbi.nlm.nih.gov/pubmed/35036121 http://dx.doi.org/10.7717/peerj.12547 |
Ejemplares similares
-
Prognostic value of immune checkpoint molecules in breast cancer
por: Fang, Jun, et al.
Publicado: (2020) -
ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021) -
Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma
por: Gao, Guangtao, et al.
Publicado: (2021) -
Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme
por: Xia, Xiangping, et al.
Publicado: (2019) -
Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis
por: Zhang, Mengyuan, et al.
Publicado: (2022)